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Summary 
This study explored the use of interleukin 2 (I1,2) and interferon ~/(IFN-3') gene-modified tumor 
cells as cellular vaccines for the treatment of bladder cancer. The mouse MBT-2 tumor used is 
an excellent model for human bladder cancer. This carcinogen-induced tumor of bladder origin 
resembles human bladder cancer in its etiology and histology, and responds to treatment in a 
manner similar to its human counterpart. Using retroviral vectors, the human I1,2 and mouse 
IFN-qr genes were introduced and expressed in MBT-2  cells.  The tumor-forming capacity of 
the cytokine gene--modified MBT-2 cells was significantly impaired, since no tumors formed in 
mice injected intradermaUy with either II.2- or IFN-y-secreting cells, using cell doses far exceeding 
the minimal tumorigenic dose of parental MBT-2 cells. Furthermore, mice that rejected the IL-2- 
or IFN-3,-secreting tumor cells became highly resistant to a subsequent challenge with parental 
MBT-2 cells, but not to 38C13 cells, a B cell lymphoma of the same genetic background. To 
approximate the conditions as closely as possible to the conditions prevailing in the cancer patient, 
inactivated cytokine-secreting cells were used to  treat animals bearing tumors established by 
orthotopic implantation of MBT-2 cells into the bladder wall of the animal. Treatment of mice 
carrying a significant tumor burden with I1.2-secreting MBT-2 cells had a significant inhibitory 
effect on tumor progression with extended survival.  Moreover, in 60% of the mice the tumor 
regressed completely and the animals remained alive and free of detectable tumor for the duration 
of the observation period. Treatment of tumor-bearing animals with I1.2-secreting MBT-2 cells 
was superior to the use of cisplatin, a chemotherapeutic agent used in the treatment of bladder 
cancer. The therapeutic effect of IFN-3,-secreting cells was minimal and treatment with unmodified 
MBT-2 cells had no effect on tumor growth or survival,  showing that the parental MBT-2 cells 
were nonimmunogenic in this experimental setting. Most importantly, mice that exhibited complete 
tumor regression after treatment with I1.2-secreting MBT-2 cells became resistant to a subsequent 
challenge with a highly tumorigenic dose of parental MBT-2  cells, indicating that long-term 
immunological memory was established in the "cured" mice. 
M 
etastasis of malignant neoplasms is responsible for most 
therapeutic failures in clinical oncology (1). Active im- 
munization protocols directed against the patient's own cancer 
cells may constitute an effective and minimally invasive treat- 
ment modality for cancer patients whose primary tumor has 
been successfully treated. Clinical studies using tumor vac- 
cines consisting of irradiated tumor cells or fractions obtained 
from tumor cells have on occasion shown clinical responses 
or prolongation of disease-free interval and survival,  but in 
general have shown little therapeutic effect and have failed 
to provide a solid foundation for future progress (2). 
The identification of soluble factors as modulators of im- 
mune responses has led to their incorporation in experimental 
protocols designed to augment antitumor immune responses. 
For example, systemic administration of I1,2, alone or in corn- 
bination with other treatments, had profound inhibitory effects 
on tumor progression in the experimental animal but exhibited 
only limited therapeutic benefit when administered to cancer 
patients  (3,  4).  The limited efficacy of I1,2 in cancer im- 
munotherapy is explained at least in part by the toxicity 
resulting from the necessity to administer high doses of the 
cytokine to the patient (5). 
Since most immunomodulators act as local hormones whose 
accumulation in the serum is prevented by virtue of their short 
half-life, it was argued that local delivery of cytokines would 
have a pronounced therapeutic benefit (6, 7). Several studies 
have attempted to induce the regression of established tumors 
or to induce immunological memory by repeated injections 
of cytokines at the site of the tumor (6-10). Overall, these 
studies have failed to demonstrate a distinct advantage for 
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approximate closely enough the physiological rate of cytokine 
secretion required to elicit an optimal immune response. An- 
other approach that would result in the highly localized secre- 
tion of cytokines at the site of the tumor would consist of 
inserting  cytokine genes into tumor cells  (11, 12).  Recent 
studies have shown that genetically engineered tumor cells 
expressing cytokines such as Ib2 (13-15),  IFN-3~ (16-18), IL-4 
(19), II:6 (20), Ib7 (21), or TNF (22) could immunize mice 
against  a subsequent challenge with parental  tumor cells. 
Many of the experimental systems used to evaluate the effec- 
tiveness ofcytokine gene-modified tumor cells as cancer vac- 
cines suffer from drawbacks that limit thdr relevance to human 
cancer:  (a)  use of animal  tumor models that  bear little,  if 
any, similarity to human cancer;  (b) use of live rather than 
inactivated  cells  in  immunization  protocols,  a  fact  also 
precluding the direct determination of the intrinsic immunoge- 
nicity of the tumor cells used in the study; (c) immunization 
of healthy animals against a subsequent challenge with pa- 
rental tumors, rather than treatment of tumor-bearing animals 
with the cytokine-secreting cells and demonstration of per- 
sistence of immunological memory in the cured animals; (d) 
heterotopic, rather than orthotopic,  implantation  of tumor 
cells; (e) measuring the growth of the primary tumor rather 
than measuring suppression of metastasis derived from the 
implanted tumor; ~  lack of controlled comparison to an es- 
tablished vaccination or treatment  protocol. 
Using an increasingly relevant animal model, Golumbek 
et al. (19) have shown that IL-4-expressing RENCA cells de- 
rived from a spontaneously arising renal cell carcinoma were 
capable of curing mice with a preestablished,  albeit small, 
tumor burden,  and that  a fraction of the cured mice were 
also resistant to a subsequent challenge with parental tumor 
cells. More recently, Porgador et al. (18, 20) have shown that 
treatment of mice with II:6 or IFN-3~ gene-modified, irradi- 
ated, tumor cell preparations derived from a Lewis lung car- 
cinoma clone (D122) was capable of suppressing  the metastatic 
spread of a preestablished  tumor, leading to the complete cure 
of a significant  fraction  of treated  animals. 
In this study we used a mouse tumor model to develop 
a cytokine gene-modified tumor vaccination strategy for the 
treatment of bladder cancer. Epidemiological studies support 
the notion that transitional cell carcinoma, the most common 
form of bladder cancer, may result from exposure to external 
carcinogens (23). Although transurethral resection followed 
by intravesical  Bacillus Calmette-Guerin  (BCG) 1 treatment 
will result in prolonged remission,  a significant fraction of 
patients  will eventually relapse locally and/or  progress  to 
metastatic disease  (24).  Some patients  with metastatic dis- 
ease respond to cytotoxic chemotherapy such as methotrexate, 
inblastin,  adriamycin,  and cisplatin,  or cisplatin plus radio- 
therapy (reviewed in reference 23). However, most complete 
responders will eventually relapse and die. Because of the se- 
rious limitations of available therapy of bladder cancer,  new 
1 Abbreviations  used  in  this paper: BCG, Bacillus Calmette-Guerin; DC, 
double copy; TK, thymidine kinase. 
approaches are clearly needed. Bladder cancer, especially pre- 
senting  as  superficial  disease,  is  responsive  to  immuno- 
therapeutic agents such as BCG (24),  and may represent  a 
good candidate for immunological intervention using tumor 
vaccines. 
The murine MBT-2 cell line,  derived from a carcinogen- 
induced bladder tumor in a C3H mouse, is an excellent model 
to evaluate new approaches  to the treatment of bladder cancer. 
The MBT-2 tumor was induced by the oral administration 
of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide  (FANFT), 
a potent carcinogen inducing bladder neoplasms in 80-90% 
of mice, and is highly specific for the urothelium (25). This 
highly malignant  tumor retains the histological appearance 
of a  poorly  differentiated  transitional  cell  carcinoma  and 
resembles, both grossly and histologically, its human coun- 
terpart.  The MBT-2 is considered a useful model,  as treat- 
ments that have shown promise in this murine model have 
been similarly  effective in human  bladder cancer  (23,  26). 
Looking toward the development of effective tumor vac- 
cines for the treatment of bladder cancer, we assessed the ability 
of IL-2 or IFN-y gene-modified MBT-2 cells to induce a state 
of immunity in the mouse against parental unmodified tumor 
cells. In this study we have shown that irradiated  IL-2, but 
not IFN-% gene-modifled MBT-2 ceils were capable of curing 
mice from a significant burden of parental tumor implanted 
orthotopically into the bladder wall. Moreover, mice cured 
from their existing tumors were resistant to a later challenge 
with a highly tumorigenic dose of parental unmodified MBT-2 
cells. 
Materials  and Methods 
A 528-bp-long DNA fragment encoding the human Ib2 cDNA 
was obtained from the plasmid pBCll/RSWAT (27) by digestion 
with restriction enzymes BamHI and HindIII. A 620-bp-long DNA 
fragment encoding the mouse IFN-3' cDNA was obtained from 
the plasmid PBRMulFNg by digestion with restriction  enzymes 
Sau3AI and SspI (28). A 852-bp-long DNA fragment  encoding 
the herpes simplex virus (HSV) thymidine kinase (TK) promoter 
was obtained from plasmid PHSV106 (29) by digestion with re- 
striction enzymes BamHI and BgllI.  A 794-bp-long DNA frag- 
ment encoding the major immediate early human CMV promoter 
was obtained from plasmid pRR23 (30) by digestion with restric- 
tion enzymes Bali and Sinai. N2 is a retroviral vector derived from 
the genome of Moloney murine leukemia virus (MoMLV), con- 
taining the bacterial neomycin resistance (neo) gene, which is used 
as a selectable marker (31). A schematic diagram presenting  the 
various vector constructs  used in these studies is shown in Fig. 
1. Vector N2/Ib2 was constructed by cloning the Ib2 cDNA into 
a unique Bcll site present upstream from the initiation  codon of 
the neo gene, generating a bicistronic transcriptional unit. The TK 
promoter-encoding  DNA fragment was fused to the IL-2 cDNA 
and cloned into a SnaBI site present in the 3' LTR of a modified 
N2 vector (32) to generate vector construct  DC/TK/Ib2.  The 
prefix DC is short  for double copy, which describes this vector 
design, where the foreign gene is inserted into the 3' LTR  of the 
retroviral vector. For more details on DC vectors see Hantzopoulos 
et al. (32). The CMV promoter--containing  DNA fragment  was 
fused to the IFN-~/cDNA fragment and cloned into a unique XhoI 
site present downstream  from the neo gene coding sequences to 
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cDNA fusion product was cloned into the SnaBI site present in 
the  3'  LTR  of  a  modified  N2  vector  to  generate  vector 
DC/TK/IFNg. DCA is a previously described vector in which the 
human ADA minigene was cloned into the 3' LTR of the N2 vector 
(32). Retroviral vector constructs were converted into corresponding 
virus by transfection into the helper-free amphotropic packaging 
cell line GP+envAM12 (33). G418-resistant  colonies were pooled, 
and vires-containing cell-free supematant was used to infect MBT-2 
cells in the presence of 8/~g/ml polybrene. Clonal derivatives of 
MBT-2 cells were isolated by G418 selection, expanded to cell lines, 
and secretion of IL-2 or IFN-3, into the cell supernatant was mea- 
sured.  Absence of replication-competent virus in  the cytokine- 
producing MBT-2 cells was shown by the inability to transfer G418 
resistance  to NIH 3T3 cells. 
Cytokine Assays.  Supernatant  from  2  x  106 semiconfluent 
cells in a 6-cm plate were collected after 48 h and assayed for the 
presence of human IL-2 or mouse IFN-3,.  Ib2 activity was deter- 
mined  using Ib2-dependent  human  primary lymphoblasts in  a 
proliferation assay as previously described (34). IFN-3, activity was 
measured using a bioassay based on its antiviral activity as deter- 
mined by the reduction of the cytopathic effects of vesicular stoma- 
titis vires on L cells (35). 
Tumor Cell Lines and Animal Studies.  The transplantable FANFT- 
induced  MBT-2  tumor  (25)  was  obtained  from  Dr.  T.  Ratliff 
(Washington University, St. Louis, MO). MBT-2 cells were grown 
in vitro in RPMI supplemented with  10%  FCS (Hyclone Labs, 
Logan, UT) and 2 mM r-glutamine. 6-8-wk-old C3H/HeJ mice 
were obtained from The Jackson Laboratory (Bar Harbor, ME). 
Tumor cell injections were done using freshly prepared tumor cells 
removed from culture plates  by trypsinization, washed twice in 
PBS, and resuspended in PBS at a concentration of 107 cells/ml. 
When indicated, cells were inactivated by irradiation (7,000 tad 
delivered  at a rate of 86 rad/min, using a 137Cs source animal it- 
radiator [Gamma Cell-40; Nordion International, Kanato, Ontario, 
Canada]). 
Orthotopic Implantation of  Ml~-2 Cells into the Bladder Wall of C3H 
Mice.  A detailed  description of the procedure will by provided 
elsewhere (Connor, J., W. Heston, E. Gilboa, and W. Fair, manu- 
script in preparation). Briefly, animals  were anesthetized by in- 
traperitoneal injection of pentabarbitol.  Under magnification, a 
0.8-cm incision was made transversely in the abdomen, just above 
the pubis.  The anterior abdominal wall muscles were incised and 
the bladder delivered into the surgical field. Using a 1.0-cc tuber- 
culin syringe, MBT-2 cells in 50/~1 of PBS were injected into the 
bladder wall. The incision was closed in one layer using a 5.0 pro- 
lene suture. The procedure was well tolerated and postoperative 
mortality was <5%. Tumors grew at the site of inoculation in all 
animals  injected  intravesically  with  104  or  more  MBT-2  cells, 
and  metastases  in  the  lung  became apparent  3  wk  posttumor 
inoculations. 
Results 
Generation of MKl:2 Cell Lines Expressing 11_,2 and IFN-T. 
Fig. I shows the retroviral vector constructs used to introduce 
and express the human I1:2 and mouse IFN-'y genes in MI~-2 
cells. The retroviral vectors used in this study were derived 
from MoMLV and are based on the high-titer N2 retroviral 
vector (31), which also contains the bacterial neo-selectable 
gene. Vector DNA was transfected into a packaging cell line 
(GP+ envAM12), and virus-containing cell-free supernatant 
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Figure  1.  Structure of retroviral vectors containing the human Ib2 or 
the mouse IFN-y cDNAs, and cytokine production in MBT-2 cells. For 
details on retroviral vector design, see Materials and Methods. Amount 
of II-2 or IFN-q/secreted by representative  clones derived from MBT-2 
cells transduced with the cytokine gene-containing vector is shown (see 
Materials and Methods). Parental MIYI'-2 cells or MBT-2  clones transduced 
with the DCA vector did not secrete detectable levels of either cytokine. 
*MBT-2 clones secreting Ib2 or IFN-~/used in subsequent studies, re- 
ferred to in the text as MBT/IL-2 or MBT/IFN-% respectively. 
was used to infect MBT-2 cells. Clones stably transduced with 
vector DNA were isolated, and expression of the I1:2 or IFN-3' 
genes  was  determined  by  measuring  the  secretion  of the 
cytokines into the cell supernatant using a bioassay for each 
cytokine (for additional details,  see Materials and Methods 
and references 14,  17,  and 32).  The amount of biologically 
active I1:2 or IFN-3' secreted from representative clones for 
each retroviral vector is listed in Fig. 1. Clones secreting the 
highest level of each cytokine, denoted by an asterisk in Fig. 1 
and referred to in the text as MBT/I1:2  and MBT/IFN-3,, 
were chosen for further studies.  Secretion of I1:2 or IFN-y 
had no discernable effects on cell morphology or on the growth 
rate of the MBT-2 cells in culture when compared to parental 
MBT-2 cells or MBT-2 cells transduced with another retroviral 
vector encoding the human ADA minigene (DCA). Parental 
MBT-2 cells or clones transduced with the control DCA vector 
did not  secrete detectable levels of either I1:2 or IFN-'y. 
Tumorigenic  Potential  of IL2-  or  IFN-7-secreting  MBT-2 
Cells.  Tumors grew progressively in all animals injected in- 
tradermally with 104 or more parental MBT-2 cells, or with 
MBT-2  cells  transduced  with  the  control DCA  retroviral 
vector. Conversely, injection of up to 10  s MBT/IL-2 or 2.5 
x  10  s MBT/IFN-3, cells failed to grow in the animal. Thus, 
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Immunized with IL-2 or IFN-  7  Cene-modified Cells 
Exp.  Injection* 
No. of parental  No. of mice with 
MBT-2  cells instilled  tumors per number 
intravesicaUy#  of mice injected 
MBT/IL-2  2  x  10  4  0/5 
MBT/IL-2  4  x  10  4  0/5 
MBT/IL-2  8  x  10  4  0/5 
MBT/IL-2  1.6  x  10  s  0/5 
MBT/IL-2  3.2  x  10  s  0/5 
Medium  2  ￿  104  5/5 
MBT/IFN-7  4  x  104  0/5 
MBT/IFN-y  8  x  104  0/5 
MBT/IFN-7  2  x  10  s  0/5 
MBT/IFN-7  4  x  105  0/5 
Medium  2  x  104  5/5 
* 10  s MBT/IL-2 or 1.5  x  10  s MBT/IFN-  7 viable cells were injected 
intradermally. 
3 wk post injection (intradermal) of cytokine-secreting cells. 
local secretion of IL-2 or IFN-7 from the genetically modified 
cells abrogated their tumorigenicity in vivo. Spleen cells de- 
rived from mice that  rejected the IL-2- or IFN-y-secreting 
tumor cells exhibited cytotoxicity in vitro against  parental 
MBT-2 cells but not against unrelated target (data not shown), 
consistent with previous studies showing that a CTL response 
was induced by the cytokine gene-modified tumor cells (13-15, 
17-20). 
IL.2-secreting MBT-2  Cells Protect Mice from  a Subsequent 
Challenge with Parental, Unmodified Tumor Cells.  In general, 
cytokine-secreting tumor cells failed to grow in the syngeneic 
host, albeit only in a number of cases were they also capable 
of immunizing mice against the parental tumor (13-22). We 
therefore examined  the ability of IL2-  or IFN-y-secreting 
MBT-2 cells to induce a protective immune response against 
parental,  unmodified MBT-2 cells.  In the experiment  sum- 
marized in Table 1, mice were injected intradermally  with 
either medium alone, with  105 live MBT/IL-2, or with  1.5 
x  10  s live MBT/IFN-y  cells.  3 wk later  mice were chal- 
lenged with increasing  doses of parental  MBT-2 cells,  and 
the appearance of a tumor at the site of injection was moni- 
tored.  In previous studies assessing  the immunogenicity  of 
cytokine gene-modified tumor cells, the tumor challenge was 
implanted at ectopic sites, usually under the skin or intrader- 
mally. It is, however, well documented that tumor cells out- 
side their natural milieu behave quite differently than in their 
organ of origin (36). To reproduce the environment that exists 
in human metastatic bladder cancer, we developed a method 
to implant  MBT-2 cells into the bladder wall of the mouse 
(intravesical  instillation).  This technique,  which consists of 
a simple surgical procedure,  is both easy and reproducible 
and will be described in detail elsewhere (Connor et al., manu- 
script in preparation).  In the animals that underwent intra- 
vesical instillation of MBT-2 cells, tumors formed significantly 
faster, metastasized earlier, and were fatal much more quickly 
than in animals that had intradermal  implantation  of cells. 
As shown in Table 1, tumors grew in all control animals 
inoculated  through  intravesical  instillation  with  2  x  104 
MBT-2 cells. On the other hand, if mice were first injected 
intradermally with II.,2- or IFN-y-secreting cells, no tumors 
formed even at very high challenge doses. The specificity of 
the protection was indicated by the fact that the growth of 
an unrelated tumor (38C13, a B cell lymphoma of the same 
genetic background)  was not  affected (data not  shown). 
IL2- and IFN-7-secreting  MBT-2 Cells Affect the Course of 
Disease in Tumor-bearing Animals.  To test the effectiveness 
of cytokine gene-modified tumor vaccines under conditions 
that would approximate the conditions prevailing in the cancer 
patient,  we sought to determine whether IL-2- or IFN-y- 
expressing MBT-2 cells are capable of affecting the course of 
disease in tumor-bearing animals.  Since the use of live tumor 
cells  as vaccines is undesirable,  the cytokine-secreting cells 
were inactivated by X-irradiation.  Immunization with inac- 
tivated cell preparations also enabled us to determine the in- 
trinsic  immunogenicity  of the unmodified MBT-2 cells. 
In the experiment  shown in Fig.  2,  tumors were estab- 
lished in the bladder of mice by intravesical  instillation  of 
2  x  104 MBT-2 cells.  7 d postimplantation  of tumor cells, 
5  x  106 irradiated  unmodified  MBT-2  cells,  or  irradiated 
cytokine-secreting cells, were injected intraperitoneally in the 
tumor-bearing  animals.  Existence of tumors in all animals 
could be established at that time by palpation, and histolog- 
ical examination in selected animals has confirmed the pres- 
ence of a vascularized tumor composed of cells resembling 
in appearance the inoculated MBT-2 cells.  Injections of ir- 
radiated cells were repeated three additional times at weekly 
intervals (Fig.  2 A, arrows). Treatment  of mice with irradi- 
ated parental MBT-2 cells had no effect on average tumor size 
(Fig. 2 A), and animals in this group and the untreated group 
died within 5-6 wk post-intravesical instillation  of MBT-2 
cells (Fig.  2 B). On the other hand, treatment of the tumor- 
bearing mice with irradiated Ib2-secreting MBT-2 cells had 
a significant inhibitory effect on tumor progression. Moreover, 
in three of five mice the tumor regressed completely, and the 
animals remained free of detectable tumor )8 wk, at which 
time they were rechallenged with MBT-2 cells (see below). 
In the other two mice the original tumors continued to grow, 
albeit more slowly, and the mice eventually died. Treatment 
of mice with IFN-y-secreting cells had a less pronounced effect 
both on tumor growth and survival.  Combined treatment 
with both IL-2- and IFN-y-secreting cells was not additive. 
Cisplatin is the most active single chemotherapeutic agent 
used in the treatment  of bladder cancer (23).  Cisplatin ex- 
hibited a modest antitumor effect in the MBT-2 model (25, 
26). It was therefore of interest to compare side by side the 
effectiveness of treatment with IL-2-secreting MBT-2 cells and 
cisplatin in mice carrying  an established tumor.  In the ex- 
periment shown in Fig. 3, mice were treated with cisplatin 
once, 7 d post-intravesical instillation of MBT-2 cells. Treat- 
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Figure  2.  Treatment  of  tumor-bearing  mice  with  cytokine 
gene-modified, X-irradiated MBT-2 cells. Tumors were established in the 
bladder of C3H mice by intravesical instillation of" 2  x  104 MBT-2 cells. 
7 d later, animals (five  mice per group) were injected intraperitoneally with 
5  x  106 X-irradiated cells that consisted of either unmodified MBT-2 cells, 
MBT/Ib2 cells, MBT/IFN-'y cells, or a combination of both MBT/IL-2 
and MBT/IFN-'y cells. Injections were repeated weekly for a total of four 
times, as indicated by the arrows. (Control)  Mice injected with PBS. (A) 
The origin and irregular shape of the bladder-induced tumors prevented 
an accurate measure of tumor size. Tumors were therefore graded on a 
relative scale of 0-5: 0, no tumor; 0.5, palpable but not visible tumor; 
1.0, small visible tumor; 2-4, increasingly larger tumors; and 5, abdomen 
full of tumor with erosion through the skin. Mice were killed when mori- 
bund. Average  tumor size  was calculated for each group of five  or remaining 
mice. (B) Survival  of mice >60 d correlated  with complete tumor regression. 
ment with irradiated  IL-2-secreting cells was initiated  14 d 
after establishment  of the  tumor,  and repeated  twice more 
at weekly intervals,  as indicated.  At the commencement of 
treatment  with  IL-2-secreting  cells  (day  14),  the  primary 
tumors were clearly visible to the naked eye, and since mac- 
rometastases can be detected in the lung 1 wk later, i.e., 3 wk 
post-intravesical instillation inoculation of tumor cells, it is 
reasonable to assume that micrometastases were already present 
in the lung at the time when treatment with IL-2-secreting 
cells was initiated.  As previously noted,  while cisplatin had 
a modest effect on tumor growth and survival (25, 26), treat- 
ment with  IL-2-secreting tumor cells had  a dramatic effect 
on  tumor  growth,  leading  to  complete  regression  of the 
14-d-old  visible tumors  in three of five animals,  which  re- 
mained free of tumor >9 wk (at which time they were again 
inoculated with MBT-2 cells, see below). The decreased effec- 
tiveness of combined treatment with cisplatin (given on day 
7) and IL-2-secreting cells (initiated on day 14) could be at- 
tributed  to  toxic effects of cisplatin. 
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Figure  3.  Treatment  of  tumor-bearing  mice  with  cisplatin and 
X-irradiated IL-2 gene-modified MBT-2 cells. Tumors were established in 
the bladders of C3H mice by intravesical instillation of 2  x  104 MBT-2 
cells. Treatment with cisplatin was performed once, at day 7. Cisplatin 
(c/s-diamine dichloroplatinum; Bristol Laboratories, Evansville, IN) was 
dissolved in sterile H20 and injected intraperitoneally using a dose of 
6 mg/kg body weight  in a total volume of 0.1 cm  2, as previously de- 
scribed (26). Intraperitoneal injections of X-irradiated MBT/IL-2  cells were 
initiated at day 14 and injections were repeated at weekly intervals twice 
more, as indicated by the arrows. Complete tumor regression occurred 
in mice that survived >60 d (B). Five mice were used in each treatment 
group, 
Since a significant proportion of tumor-bearing mice were 
apparently cured by treatment with IL-2-secreting MBT-2 cells, 
it was of interest  to test whether  such mice would be pro- 
tected from a  second challenge  with  a highly  tumorigenic 
dose of parental MBT-2 cells.  When  mice exhibiting  long- 
term tumor regression were rechallenged via intravesical in- 
stillation with parental MBT-2 cells, no tumor growth was 
observed in nine of nine mice tested. By contrast, five of five 
age-matched control mice inoculated with fivefold less MTB-2 
cells developed a tumor at the site of inoculation  (Table 2). 
This result indicates that immunological memory was estab- 
lished  in  the  tumor-bearing  mice  treated  with  inactivated 
IL-2-secreting cells. 
Discussion 
Although  recent  studies  have  shown  that  cytokine 
gene-modified tumor cells are capable of immunizing mice 
against the parental tumor,  the choice of the animal model 
and/or the experimental design used have often limited their 
1131  Connor et al. relevance to human cancer. The emphasis in the current study 
was to test the effectiveness of cytokine gene-modified tumor 
cells as cellular vaccines using an animal model and an ex- 
perimental design that approximates as closely as possible the 
conditions prevailing in the cancer patient. The MBT-2 mouse 
tumor model used in this work is an excellent model for human 
bladder cancer, not only because this carcinogen-induced  tumor 
of  bladder origin resembles in its etiology and histology bladder 
cancer in humans, but also because the MBT-2 tumor responds 
to treatment in a manner similar to its human counterpart 
(23,  26). 
In this study we have shown that intradermal injection 
of I1-2 gene-modified MBT-2 cells into tumor-bearing animals 
is capable of curing mice with a considerable tumor burden 
(Figs.  2 and 3). Most importantly, the mice cured of their 
tumor became resistant to a subsequent challenge with a very 
high dose of parental MBT-2 cells, indicating that immuno- 
logical memory persisted in the cured mice (Table 2). Since 
recurrence of metastatic, and in some cases local, disease is 
the major cause of death in cancer patients, this observation 
suggests that cytokine gene-modified tumor vaccines could 
provide protection to the cancer patient (in remission) against 
minimal residual disease. 
The effectiveness  of cytokine gene-modified tumor vac- 
cines in tumor-bearing animals was demonstrated in recent 
studies.  Golumbek et  al.  (19) have shown that  live  I1-4- 
expressing RENCA cells (a renal cell carcinoma cell line) were 
capable of curing mice from a small burden of tumor, and 
that 50% of the cured mice were resistant to a subsequent 
challenge with parental tumor cells. Porgador et al. (18, 20) 
have shown that treatment of mice with inactivated I1-6 or 
IFN-y-expressing D122 cells (a Lewis lung carcinoma-derived 
cell line), but not unmodified tumor cells, had a significant 
inhibitory effect on preestablished lung micrometastases, and 
led to the complete cure of a significant proportion of mice. 
Additional features of this experimental system increase its 
relevance to human cancer. In this study cytokine-secreting 
cells inactivated by irradiation were used to treat tumor-bearing 
animals. Previous studies, with the notable exception of those 
by Porgador et al. (18, 20), have used live cytokine-secreting 
cells as immunogens. Ths use of live tumor cells as cellular 
vaccines in cancer patients is of course undesirable. In animal 
models, live cells could be used to immunize because cytokine- 
secreting  cells  lose  their  in  vivo  growth  potential,  i.e., 
tumorigenicity. In studies in which live cytokine-secreting 
cells were used as immunogens, the intrinsic immunogenicity 
of the tumor cells could not be determined, and therefore 
it was unclear whether the cytokine contributed to the in- 
duction of antitumor immunity or whether its only func- 
tion was to inhibit tumor growth in the mouse. In view of 
the fact that  spontaneously arising tumors are apparently 
nonimmunogenic (although bladder tumors may be consid- 
ered weakly immunogenic since they respond to treatment 
with BCG [24]), the use of even weakly immunogenic tumor 
cells in animal models is undesirable (37).  Using irradiated 
tumor cells, we could show that unmodified MBT-2 cells were 
nonimmunogenic in the experimental setting used and that 
the protective effect seen in tumor-bearing animals could be 
attributed to the action of I1-2 (Fig.  2).  It is interesting to 
note in this regard that IFN-y was more effective than I1-2 
in reducing the tumorigenicity of MBT-2 cells (up to 2.5  x 
105 IFN-3/-secreting  cells injected intradermaUy did not form 
a tumor compared with only 1.0  x  10  s IL-2-secreting cells). 
Nevertheless, irradiated I1,2-secreting MBT-2 cells were su- 
perior to IFN-3~-secreting  cells in the treatment of tumor- 
bearing mice (Fig. 2). This is a clear indication that different 
cellular mechanisms are responsible for the observed antitumor 
effect  and  the  immunogenic  potential  of  the  cytokine- 
expressing tumor cell. 
Another important feature of this experimental system was 
that the parental MBT-2 tumor cells were implanted ortho- 
topically into the mouse bladder. It is well recognized that 
the site of implantation of the tumor can greatly influence 
its properties and that orthotopic implantation represents a 
more accurate model to follow in vivo behavior (36). Indeed, 
MBT-2 cells injected intradermally or subcutaneously grow 
slowly and metastasize poorly. In contrast, when injected into 
the bladder wall of the mouse, they grow faster and metasta- 
size extensively to the lung, mimicking more closely the be- 
havior of metastatic human bladder cancer. 
To assess the effectiveness of a new treatment strategy, com- 
parison with an established treatment protocol is highly in- 
formative. We therefore compared side by side the effective- 
ness of I1-2 gene-modified MBT-2 cells with that of cisplatin, 
a commonly used chemotherapeutic agent used in the treat- 
ment of cancer, including bladder cancer (23). The superior 
effect elicited by I1,2 gene-modified MBT-2 cells compared 
with that ofcisplatin is evident (Fig. 3), further recommending 
for consideration this form of immunotherapy for the treat- 
ment of bladder cancer. 
Although the use of tumor-bearing mice as subjects of im- 
munological intervention enhances the relevance of this an- 
imal model to human cancer, initiation of treatment with 
I1-2-secreting MBT-2 cells shortly after establishment of the 
parental tumor in the bladder of the experimental mouse fails 
to take into account the fact that cancer patients generally 
become candidates for immunotherapy after a long history 
of disease, including treatments designed to reduce the tumor 
burden present at the time of diagnosis. The concern has been 
raised that such individuals may be in a state of generalized 
or tumor-specific immunosuppression (38,  39),  and there- 
fore the question, not addressed in our experimental design, 
is whether treatment with cytokine-secreting cells would also 
be able to reverse a possible state of immune unresponsive- 
ness.  However, patients with recurrent superficial  bladder 
cancer refractory to currently available intravesical  therapies 
are not in a state of generalized immunosuppression and may 
represent a patient population suitable for such treatment. 
This approach has the added advantage that,  if successful, 
it would enable bladder preservation and avoid the signifi- 
cant psychologic sequelae of radical cystectomy and urinary 
diversion. 
In summary, the murine bladder model described in this 
study represents an improved model to evaluate the effective- 
1132  Bladder Tumor Regression  in Interleukin  2 Gene-treated Mice ness of cytokine gene-modified tumor vaccine. It would be 
of particular interest to evaluate in this experimental system 
the use of additional promising cytokines such as IL-6 (20), 
as  well  as  combinations  of cytokines.  Such  studies  are  in 
progress. 
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